Source: International Congress 2016 – Airway response to infection
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Nurhan Sarioglu (Balikesir, Turkey), Nurhan Sarioglu, Fatma Bahar Sunay, Oguzhan Korkut, Fuat Erel, Adnan Adil Hismiogullari, Mehmet Köse. Assesment of the effects of tocilizumab, adalimumab and steroid in LPS induced acute lung inflammation. Eur Respir J 2016; 48: Suppl. 60, 3980

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of dexamethasone, roflumilast and azithromycin in a murine cigarette smoke/NTHi infection model Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Repeated lipopolysaccharide stimulation causes corticosteroid insensitive inflammation in lung via phosphoinositide-3-kinase δ signaling Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 The effects of intra-nasally administered anti-inflammatory compounds in a mouse model of acute COPD exacerbations Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Pre-clinical to clinical potency of AZD7624 in LPS induced TNFa response Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Effect of mast cells degranulation blockade on the inflammatory response outcome in the COPD model Source: International Congress 2016 – New signalling pathways in COPD Year: 2016 IL33 and TSLP involvements in influenza-induced exacerbation in a murine model of chronic asthma Source: International Congress 2015 – Advances in asthma and allergy in animal models Year: 2015 Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for the pathogenesis of allergic airways disease Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 The anti-inflammatory effects of PF03715455 and roflumilast on both cellular and tissue inflammation in a mouse model of COPD Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Influenza induced exacerbation is associated with steroid insensitive AHR and pulmonary inflammation in HDM-sensitised mice Source: International Congress 2016 – Immune responses in the lung Year: 2016 The role of proinflammatory cytokines in severe COPD patients before and after roflumilast treatment Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Effect of roflumilast on airway remodeling in a murine model of chronic asthma Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors Source: International Congress 2014 – Asthma and COPD management Year: 2014 The combination of TNF-α neutralization and dexamethasone treatment restored the corticosteroid responsiveness in tobacco smoking mice Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action Year: 2016 Effect of MSC treatment on LPS-induced inflammation, emphysema and atherosclerosis in E3L mice Source: International Congress 2015 – The multiple facets of stem and progenitor cells in lung health and disease Year: 2015 The effect of lipopolysaccharide-contaminated ovalbumin on airway inflammation and remodeling in a chronic murine asthma model Source: Annual Congress 2013 –Murine models of lung immunology Year: 2013 Treatment with Syk inhibitors after establishment of disease phenotype in a chronic HDM model of allergic airways inflammation abolishes AHR and attenuates inflammatory mediator expression Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Effects of tobacco smoke and poly IC, alone and in combination, on mouse lung pathology Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013